Silvio Roggo Pages 359 - 370 ( 12 )
The first proteolytic step in the processing of amyloid precursor protein (APP) to amyloid-beta (Aβ) in the brain is performed by β-site APP cleaving enzyme (BACE1). This enzyme is a membrane bound aspartic protease with high homology of the catalytic domain to renin and pepsin and of yet unknown physiologic function. It is a primary drug discovery target for Alzheimers disease therapy. The first potent inhibitors are based on the sequence of APP around the β-secretase cleavage site EVNL / DAEF, with the scissile Leu-Asp amide bond being replaced by a hydroxyethylene transition state analogue isostere. In addition, lipophilic sidechains have been incorporated and a crystal structure of such an octapeptidic inhibitor bound in the active site is already available. Recent progress in the field of BACE inhibition is reviewed.
bace, aspartic protease, inhibition, app, amyliod, pepstatin, protease, indinavir, amprenavir, tipranavir, aliskiren
Novartis Pharma AG, WSJ-507.605A, Lichtstrasse 35, CH-4056 Basel, Switzerland